Ixtlan BioScience
Psilocybin-based Treatments for Brain Pathologies
Company Overview
Snapshot
Founded in April 2020 by Yehonatan Cavens, Itamar Bar-Av Borochov, Shlomo Pekar, and Ana Parabucki, Ixtlan BioScience operates with 1–10 employees. The company is currently in a Pre-Funding stage. In December 2021, Ixtlan BioScience announced the filing of a new patent for psilocybin treatment of Alzheimer's disease and brain pathologies, signaling its focus on intellectual property in the psychedelic medicine space.
Business overview
Ixtlan BioScience is a Health Tech & Life Sciences company focused on developing psilocybin-based treatments for Alzheimer's disease and other brain pathologies. The company's core technology involves defining and utilizing psilocybin micro-dosing to create a new class of safe and accessible mental health therapies aimed at slowing the progression of Alzheimer's and dementia diseases. Operating within the Pharmaceuticals sector, Ixtlan BioScience serves the healthcare and life sciences industries, with a primary product being the Ixtlan AD Kit.
Strategic signal
In December 2021, Ixtlan BioScience announced the filing of a new patent for the psilocybin treatment of Alzheimer's disease and other brain pathologies. This development highlights the company's strategic commitment to intellectual property in the emerging field of psychedelic medicine, indicating a focus on securing its therapeutic approach for neurodegenerative conditions. For investors, this signals a foundational step in establishing market defensibility and potential future value in a rapidly evolving therapeutic area.
Log in to access full profile ›Company Intelligence Q&A
- What is Ixtlan BioScience's primary focus?
- Ixtlan BioScience is focused on developing psilocybin-based treatments for Alzheimer's disease and other brain pathologies, aiming to create new mental health therapies.
- When was Ixtlan BioScience founded and by whom?
- Ixtlan BioScience was founded in April 2020 by Yehonatan Cavens, Itamar Bar-Av Borochov, Shlomo Pekar, and Ana Parabucki.
- What significant intellectual property development did Ixtlan BioScience announce?
- In December 2021, Ixtlan BioScience announced the filing of a new patent for the psilocybin treatment of Alzheimer's disease and brain pathologies.
- What is the current operational status of Ixtlan BioScience?
- Ixtlan BioScience is currently Non Active, having ceased to operate in August 2024.
- What is Ixtlan BioScience's product development stage?
- Ixtlan BioScience is currently in the R&D product stage, with a primary product identified as the Ixtlan AD Kit.